



## CLINICAL GUIDELINE

# Retinal Vein Occlusion Management Guidelines

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

<b>Version Number:</b>	4
<b>Are there changes to the clinical content of this version:</b>	No
<b>Date Approved:</b>	12 <sup>th</sup> February 2021
<b>Date of Next Review:</b>	12 <sup>th</sup> February 2024
<b>Lead Author:</b>	David Gilmour
<b>Approval Group:</b>	Ophthalmology Clinical Governance Group

### Important Note:

The Intranet version of this document is the only version that is maintained. Any printed copies should therefore be viewed as 'Uncontrolled' and as such, may not necessarily contain the latest updates and amendments.

## RETINAL VEIN OCCLUSION MANAGEMENT GUIDELINES

### History (risk factors)

Age  
Hypertension  
Hyperlipidaemia  
Diabetes  
Smoking  
Glaucoma

### Examination

BCVA  
RAPD  
IOP  
Gonioscopy (Open vs closed vs NVA)  
Rubeosis  
Dilated fundal exam

### Baseline Investigations

FBC  
U&E  
CRP  
ESR  
Random Glucose  
Lipids  
BP  
OCT  
Further Ix if History suggests  
In young patients, consider FFA to exclude vasculitis

Discuss with medical retina team regarding follow up and further treatment.

All patients must be given Glasgow Macular Service leaflet and advised to get in contact if vision deteriorates.